Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings Classification · 86% confidence The document is a board meeting outcome notice filed under SEBI Listing Regulations (Reg. 30 & 33) announcing and enclosing the audited financial results (standalone & consolidated) and the auditors’ report, along with a dividend recommendation. It is a regulatory stock‐exchange filing rather than a full annual report (10‐K), standalone management discussion, or mere summary earnings release. It also exceeds the length of a brief report announcement, so it best fits the catch‐all Regulatory Filings category (RNS).
2026-05-18 English
Outcome of Board Meeting held on May 18, 2026 - Recommendation of Final Dividend
Audit Report / Information Classification · 90% confidence The document is the formal disclosure of audited financial results under SEBI Listing Regulations 30 and 33. It contains the Board’s approval of the standalone and consolidated audited results for the quarter and year ended March 31, 2026, along with the full Independent Auditor’s Report by B S R & Co. LLP. This is not a simple report‐publication announcement (as the audit report is included in full), nor a standard earnings release of highlights, but a standalone audit report on financial results. Therefore, it fits the “Audit Report / Information” (AR) category.
2026-05-18 English
Outcome of Board Meeting of the Company held on May 18, 2026
Audit Report / Information Classification · 90% confidence The document is a SEBI listing‐regulated filing dated May 18, 2026, titled “Outcome of Board Meeting” which approves and encloses the Audited Financial Results (Standalone & Consolidated) and the Independent Auditor’s Report for the quarter and financial year ended March 31, 2026. It does not contain a full annual management discussion or the breadth of an Annual Report (10‐K), nor is it merely a short announcement or dividend notice. Instead, it provides the actual audit opinion, basis for opinion, and auditor responsibilities, fitting the definition of an Audit Report / Information.
2026-05-18 English
Update to Earnings Call Intimation dated May 11, 2026 - Correction in the US Time
Regulatory Filings Classification · 88% confidence The document is a brief stock exchange filing providing a correction to the timing of an investor earnings call (not the call transcript itself, nor the earnings release). It does not contain financial results or report data, nor is it an AGM notice or dividend declaration. It is an announcement to the exchanges, fitting the fallback category for miscellaneous regulatory announcements.
2026-05-18 English
General Updates
Regulatory Filings Classification · 85% confidence The document is a formal stock exchange filing notifying a correction to previously announced earnings call timing. It does not contain any financial results or presentation materials, nor does it represent the earnings release itself. It is a regulatory update/correction, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-18 English
Earnings Call to discuss the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.
Regulatory Filings Classification · 72% confidence The document is an announcement to stock exchanges and investors scheduling an earnings call to discuss audited financial results. It contains no actual financial data or highlights, nor is it the release of results itself (so it is not an ER), and it is not a transcript (CT). It is an event notice, thus falling under the catch‐all Regulatory Filings (RNS) category.
2026-05-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.